Online inquiry

IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7909MR)

This product GTTS-WQ7909MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7909MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7502MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ14557MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ843MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ3733MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ436MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ158MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ6105MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ7575MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW